International Immunopharmacology · 2021 · 126 citations · 47 references
PharmacyImmunologyOncologyImmuno-oncology PharmacotherapyImmunoregulationImmunotherapyAdverse Drug Reaction ReportingAdverse Event AnalysisAdverse Event ReportingCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune-related Adverse EventsAdverse Event Data ReviewAdverse Event Reporting FormsAdverse Event Reporting StandardsImmune Checkpoint ReceptorsImmune Checkpoint ResistanceImmune-mediated Adverse EventsImmune-related Adverse Event AssessmentImmune-related Adverse Event Grading
47
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2015 · 8.1K citations · Full text
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok, Harriet M. Kluger, Margaret K. Callahan et al. · New England Journal of Medicine · 2013 · 4.2K citations · Full text
Medicine, Oncology, Pharmacology +17
Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider et al. · Journal of Clinical Oncology · 2018 · 3.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg et al. · The Lancet · 2016 · 2.2K citations · Full text
Medicine, Oncology, Pharmacology +11